Literature DB >> 15074839

Osteoporotic cytokines and bone metabolism on rats with induced hyperthyroidism; changes as a result of reversal to euthyroidism.

Gönül Simsek1, Yesari Karter, Seval Aydin, Hafize Uzun.   

Abstract

Hyperthyroidism is characterized by increased bone turnover and resorptive activity. Raised levels of serum osteoporotic cytokines, such as interleukin (IL) -1beta, IL-6 and tumor necrosis factor (TNF)-alpha have been demonstrated previously in hyperthyroidism. These elevations are controversial and it is difficult to differentiate the contribution of thyroid hormones to the elevation of cytokines from that of the autoimmune inflammation in Graves' disease (GD) and follicular cell damage in thyroiditis. Therefore, we investigated the effect of thyroid hormones on serum IL-1beta, IL-6, TNF-alpha levels and bone metabolism on L-thyroxine induced hyperthyroid rats and changes in cytokine levels and bone metabolism on the same rats after reversal to euthyroidism. Rats were treated with L-thyroxine for 5 weeks (0.4 mg/ 100 g food). Plasma T3, T4, TSH and serum IL-1beta, IL-6, TNFalpha, Calcium (Ca), phosphorous (P), parathyroid hormone (PTH), alkaline phosphatase (ALP), bone alkaline phosphatase (B-ALP) levels were measured and differential leucocyte counts were made initially, at the 5th week of the experiment (hyperthyroid state) and 5 weeks after quitting the administration of L-thyroxine (euthyroid state). Significant rises in serum IL-1beta, IL-6 and TNFalpha were noted in hyperthyroidism (P < 0.001). In euthyroid state, IL-15, IL-6 and TNFalpha decreased significantly, but IL-beta and TNFalpha were significantly higher than the baseline values (P < 0.05) while IL-6 levels turned back to the baseline values. Plasma T3 and T4 levels were significantly correlated with serum cytokines in hyperthyroid state while there was no correlation in euthyroid states. Ca and P levels did not differ significantly while PTH levels declined significantly in the hyperthyroid state (P < 0.05). After the reversal to the euthyroidism, there was no significant change in Ca, P and PTH levels. ALP and B-ALP increased significantly in hyperthyroidism (P < 0.001, P < 0.01) and they did not decrease in euthyroid state. The lymphocyte number and ratio in differentials increased significantly in the hyperthyroid state (P < 0.001). In euthyroidism they decreased significantly (P < 0.001) but it was significantly higher than the baseline value (P < 0.05). Our findings showed that the deleterious effect on bone metabolism in hyperthyroidism might be mediated by cytokines and the increased bone turnover in hyperthyroidism failed to decrease despite euthyroidism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15074839

Source DB:  PubMed          Journal:  Chin J Physiol        ISSN: 0304-4920            Impact factor:   1.764


  5 in total

1.  The role of IL-15 and selenium in Graves ophthalmopathy.

Authors:  Se Jin Park; Jae Il Shin
Journal:  Nat Rev Endocrinol       Date:  2011-11-23       Impact factor: 43.330

2.  TNFalpha mediates the skeletal effects of thyroid-stimulating hormone.

Authors:  Hidenori Hase; Takao Ando; Leslie Eldeiry; Alina Brebene; Yuanzhen Peng; Lanying Liu; Hitoshi Amano; Terry F Davies; Li Sun; Mone Zaidi; Etsuko Abe
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-14       Impact factor: 11.205

3.  Down-regulation of ribosomal protein L7A in human osteosarcoma.

Authors:  Shui-er Zheng; Yang Yao; Yang Dong; Feng Lin; Hui Zhao; Zan Shen; Yuan-jue Sun; Li-na Tang
Journal:  J Cancer Res Clin Oncol       Date:  2009-01-06       Impact factor: 4.553

4.  Atypical thyrotropin-secreting pituitary microadenoma revealed by severe osteoporosis in a young man.

Authors:  Alexis de Rougemont; Marie-Gabrielle Mourot; Jean-Paul Riou
Journal:  J Bone Miner Metab       Date:  2009-02-28       Impact factor: 2.626

Review 5.  Secretory Autophagy and Its Relevance in Metabolic and Degenerative Disease.

Authors:  Claudio Daniel Gonzalez; Roxana Resnik; Maria Ines Vaccaro
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-05       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.